Intellia Therapeutics Inc (NTLA)

NASDAQ

$10.92

Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.

Sector:

Industry:

68 analysts

Buy

Target: $26.17 (+139.65%)

Market Cap

$1.57B

FCF 5Y CAGR

+39.47%

Free Cash Flow Yield

-23.15%

Beta (5Y)

1.77

Adjust inflation

Log

Valuation

Market Cap$1.57B

P/S28.12

P/B2.93

Profitability

Total Revenue (TTM)$66M

Gross Profit (TTM)-$231M

EBITDA-$411M

Operating Margin-668%

EPS-$3.46

Financial Health

Free Cash Flow Yield-23.15%

Growth & Risk

EPS 5Y CAGR+8.10%

Revenue 5Y CAGR+5.11%

FCF 5Y CAGR+39.47%

Beta (5Y)1.77

Sharpe Ratio0.40